Coding sequence of recombinant protein, recombinant protein, preparation method, recombinant strain and application
By using recombinant proteins from zebrafish Fgf11a or mouse FGF11b, the problems of low vascular factor expression and limited number of blood vessels after spinal cord injury were solved, and the effect of significantly increasing vascular formation was achieved.
Patent Information
- Application Number
- CN202510631140.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-05-16
- Publication Date
- 2025-06-13
- Estimated Expiration
- 2045-05-16
AI Technical Summary
The expression level of vascular factors after spinal cord injury is low, and the number of pro-regeneration blood vessels repaired by conventional drug treatment is limited.
A recombinant protein is provided, and its coding sequence is derived from zebrafish Fgf11a or mouse FGF11b. The coding sequence is obtained by PCR amplification or gene synthesis, and recombined to a prokaryotic expression vector using a homologous arm to express and purify the recombinant protein.
Recombinant proteins can significantly increase the expression level of vascular factors after spinal cord injury, significantly increase the number of blood vessels, and promote vascular formation after spinal cord injury.
Smart Images

Figure CN120137000A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of genetic engineering, and in particular to a coding sequence of a recombinant protein, a recombinant protein, a preparation method, a recombinant strain and an application thereof. Background Art
[0002] Spinal cord injury (SCI) is a severe nerve trauma with a high disability rate. After injury, the local microenvironment is damaged, leading to the rupture of the vascular network, and then ischemia, hypoxia and blood-spinal cord barrier dysfunction are triggered. These pathological changes cause inflammatory cells to infiltrate into the injury site, exacerbating the inflammatory response. Angiogenesis can restore blood supply to the damaged area, improve the local microenvironment, and support neuron survival and axon regeneration. Therefore, in the early stage (3 - 7 days) after injury, timely vascular intervention can optimize the local vascular structure and blood supply, reducing cell loss and nerve function defects.
[0003] After spinal cord injury, the expression level of vascular factors is low, and the number of pro-regenerative blood vessels repaired by conventional drug treatment is limited. Fibroblast growth factors (FGFs) play important roles in various biological processes, including cell proliferation, metabolism and differentiation. FGFs are divided into paracrine, endocrine and intracellular subfamilies. Previous studies have shown that FGFs alone or in combination treatment exhibit obvious therapeutic effects in SCI animal models. Different from other FGFs subfamilies, intracellular FGFs (iFGFs, FGF11 - FGF14) act intracellularly without activating FGFs receptors. iFGFs are expressed in a variety of cells, including neurons, cardiomyocytes, osteoclasts and fibroblasts. However, most studies have focused on their role as regulators of voltage-gated ion channels in the nervous system. However, recent studies have begun to reveal their potential role in angiogenesis. Different from mammals, zebrafish have a strong nerve regeneration ability, and even in adults, they can recover normal swimming activities within 6 - 8 weeks after spinal cord injury. However, the functions of Fgfs derived from zebrafish have rarely been studied. Summary of the Invention
[0004] In order to overcome the above deficiencies that the expression level of vascular factors is low after spinal cord injury and the number of pro-regenerative blood vessels repaired by conventional drug treatment is limited, the present invention provides a recombinant protein that can significantly increase the expression level of vascular factors after spinal cord injury, and the number of blood vessels increases significantly, promoting the good effect of blood vessel formation after spinal cord injury.
[0005] In order to achieve the above object, the present invention adopts the following technical solutions: A coding sequence of a recombinant protein, comprising: the coding sequence shown in SEQ ID NO.01 or SEQ ID NO.03.
[0006] The present invention also discloses a recombinant protein, which is prepared using the coding sequences shown in SEQ ID NO.01 or SEQ ID NO.03, and the amino acid sequence of the recombinant protein is shown in SEQ ID NO.02 or SEQ ID NO.04.
[0007] The present invention also discloses a method for preparing a recombinant protein, comprising the following steps: a. The zebrafish Fgf11a nucleotide sequence or the mouse FGF11b nucleotide sequence is respectively obtained by PCR amplification or gene synthesis to obtain the coding sequences shown in SEQ ID NO.01 or SEQ ID NO.03; b. Recombinant to the prokaryotic expression vector using homologous arms to obtain the corresponding recombinant plasmid vectors respectively.
[0008] Optionally, the primers used in the PCR amplification operation include the primers shown in SEQ ID NO.05 or SEQ ID NO.06.
[0009] Optionally, the primers used in the homologous arm recombination operation include the primers shown in SEQ ID NO.07, SEQ ID NO.8, SEQ ID NO.9 or SEQ ID NO.10.
[0010] Optionally, the method for preparing a recombinant protein of the present invention further includes step c, and the operation method of step c includes: after transforming the engineering bacteria, picking monoclonal colonies and inoculating them into an auto-inducing complex medium for culture, and centrifuging to collect the bacterial cells.
[0011] Adding bacterial lysate to the bacterial cells, then sonicating to lyse, and obtaining a precipitate; after washing the precipitate, adding a urea solution, and dissolving it by shaking overnight and centrifuging to collect the supernatant; loading the supernatant onto a column, washing away the impurity proteins, eluting and collecting the purified protein.
[0012] Optionally, the method for preparing a recombinant protein of the present invention further includes step d, and the operation method of step d includes: placing the purified protein in a dialysis bag and soaking it in a gradient dialysis buffer solution for dialysis.
[0013] The present invention also discloses a recombinant strain containing the coding sequences shown in SEQ ID NO.01 or SEQ ID NO.03.
[0014] The present invention also discloses the application of a recombinant protein in promoting angiogenesis after spinal cord injury.
[0015] The beneficial effects of the present invention at least include: the recombinant protein can significantly increase the expression level of vascular factors after spinal cord injury, and the number of blood vessels increases significantly, showing a good effect in promoting angiogenesis after spinal cord injury. Brief Description of the Drawings
[0016] Figure 1 is the detection diagram of prokaryotic expression of the recombinant protein of the present invention; Figure 2 is the schematic diagram of the effect of the recombinant protein of the present invention on angiogenesis of HUVEC cells; Figure 3 is the schematic diagram of the protein expression at the spinal cord injury site 4 days after injection of the recombinant protein of the present invention; Figure 4 is the VEGFA protein level diagram at the spinal cord injury site 4 days after injection of the recombinant protein of the present invention; Figure 5 is the immunofluorescence detection diagram of CD31 at the spinal cord injury site 4 days after injection of the recombinant protein of the present invention; Among them: M, marker; 1, culture medium; 2, bacterial cells; 3, supernatant after cell disruption; 4, precipitate after cell disruption; 5, protein after purification by nickel column. Figure 1 In which: M, marker; 1, culture medium; 2, bacterial cells; 3, supernatant after cell disruption; 4, precipitate after cell disruption; 5, protein after purification by nickel column. Detailed Description of the Invention
[0017] The present invention will be further described below in conjunction with the drawings and specific embodiments. The raw materials and equipment used in the following specific embodiments of the present invention are all known products and are obtained by purchasing commercially available products. The engineering bacteria in the present invention use Transetta(DE3) Chemically Competent Cell of Beijing TransGen Biotech Co., Ltd. Transetta(DE3) is an imported strain produced by a special process and can be used for chemical transformation of DNA. The cells have chloramphenicol (Camr) resistance. Using pUC19 plasmid DNA for detection, the transformation efficiency can reach 107 cfu / μg DNA. Using Control Plasmid I (Amp+) to detect whether the cells have the expression function, and the size of the expressed protein is 25 kDa. In the present invention, SDS-PAGE is the abbreviation of sodium dodecyl sulfate-polyacrylamide gel electrophoresis, which is mainly used for separating and analyzing the components in a protein mixture. In the present invention, Tris-HCl, that is, tris(hydroxymethyl)aminomethane hydrochloride, is a commonly used buffer and can use the products of Solarbio Science & Technology Co., Ltd. The BCA kit of the present invention can purchase the BCA kit of Beyotime Biotechnology Co., Ltd. The PBS buffer solution can purchase the products of Solarbio Science & Technology Co., Ltd. In the present invention, western blot is immunoblotting. Immunoblotting, also known as Western blotting, is a method for detecting a certain protein in a complex sample based on the specific binding of antigen and antibody. The OCT embedding agent can use the products of Epredia Experimental Instruments Manufacturing (Shanghai) Co., Ltd.
[0018] In the present invention, PFA (paraformaldehyde) can be purchased from Solarbio Science & Technology Co., Ltd. BSA (bovine serum albumin) can be obtained from Thermo Fisher Scientific Inc. The laser confocal C2-2 instrument can be the C2si from Nikon. The Loading solution in the present invention is a loading buffer. In the present invention, CD31 (also known as PECAM-1, Platelet Endothelial Cell Adhesion Molecule-1) is a transmembrane glycoprotein mainly expressed on the surface of endothelial cells and is a specific marker for vascular endothelial cells, widely used for detecting angiogenesis (such as tumor angiogenesis, tissue repair, etc.). In this detection, the primary antibody: anti-CD31 antibody (the species should match the sample source, such as mouse anti-human CD31 monoclonal antibody); the secondary antibody: a fluorescently labeled secondary antibody (such as Alexa Fluor 488 / 594-labeled anti-mouse IgG); the blocking solution: 1-5% BSA; the mounting medium: an anti-fluorescence quencher containing DAPI (such as Southern Biotech) PBS buffer (pH 7.4).
[0019] The present invention discloses a coding sequence of a recombinant protein, including: the coding sequence shown in SEQ ID NO.01 or SEQ ID NO.03. SEQ ID NO.01 or SEQ ID NO.03 of the present invention is shown in the sequence listing. The nucleotide sequence of SEQ ID NO.01 corresponds to the nucleotide sequence XM_021477520.1 of zebrafish Fgf11a (ZFgf11a) (this nucleotide sequence is publicly available on NCBI and was collected by the inventor himself, see the disclosure table of genetic resource sources for details), and the nucleotide sequence shown in SEQ ID NO.03 corresponds to the nucleotide sequence NM_001291104.2 of mouse FGF11b (MFGF11b) (this nucleotide sequence is publicly available on NCBI and was obtained by purchasing on the market, see the disclosure table of genetic resource sources for details).
[0020] A recombinant protein is prepared using the coding sequence shown in SEQ ID NO.01 or SEQ ID NO.03, and the amino acid sequence of the recombinant protein is as shown in SEQ ID NO.02 or SEQ ID NO.04. SEQ ID NO.02 and SEQ ID NO.04 of the present invention are shown in the sequence listing.
[0021] The present invention also discloses a recombinant strain containing the coding sequence shown in SEQ ID NO.01 or SEQ ID NO.03.
[0022] The primers used for PCR amplification in the present invention are shown in Table 1 below: Table 1 Primers used for PCR amplification in the present invention 。
[0023] The primers used for homologous arm recombination in the present invention are shown in Table 2 below: Table 2 Primers used for homologous arm recombination in the present invention 。
[0024] The present invention discloses a method for preparing a recombinant protein, comprising the following steps: a. According to the published nucleotide sequences of zebrafish Fgf11a (ZFgf11a) XM_021477520.1 and mouse FGF11b (MFGF11b) NM_001291104.2 in the NCBI database, the coding sequences of ZFgf11a and MFGF11b are obtained by PCR amplification or gene synthesis respectively.
[0025] The primers used in the PCR amplification operation include the primers shown as ZFgf11a-F1 and ZFgf11a-R1.
[0026] b. After purification, it is recombinated into the prokaryotic expression vector pET-30a(+)-GFP by homologous arm to obtain the recombinant plasmids pET-30a(+)-GFP-ZFgf11a and pET-30a(+)-GFP-MFGF11b. The primers used in the homologous arm recombination operation include the primers shown as ZFgf11a-F2, ZFgf11a-R2, MFGF11b-F2 or MFGF11b-R2.
[0027] c. Transform the recombinant protein expression vector into engineering bacteria, and screen to obtain recombinant protein expression strains; after transforming the engineering bacteria, pick monoclonal colonies and inoculate them into an auto-inducing complex medium, and culture under predetermined conditions; centrifuge to collect the bacterial cells; add bacterial lysis solution to the bacterial cells, and then ultrasonically lyse to obtain a precipitate; wash the precipitate and then add urea solution, and dissolve it by shaking overnight and centrifuge to collect the supernatant; load the supernatant onto a column, wash the column with urea solution to wash away the impurity proteins, elute and collect the purified protein.
[0028] d. Place the purified protein in a dialysis bag and soak it in a gradient dialysis buffer solution for dialysis.
[0029] Example 1: A method for preparing a recombinant protein, comprising the following steps: a. According to the published nucleotide sequence of zebrafish Fgf11a (ZFgf11a) XM_021477520.1 in the NCBI database, the coding sequence of ZFgf11a is obtained by PCR amplification.
[0030] The primers used in the PCR amplification operation include the primers shown as ZFgf11a-F1.
[0031] b. After purification, it was recombined into the prokaryotic expression vector pET-30a(+)-GFP using homologous arms to obtain the recombinant plasmid pET-30a(+)-GFP-ZFgf11a. The primers used in the homologous arm recombination operation include the primers shown as ZFgf11a-F2 and ZFgf11a-R2.
[0032] c. The recombinant protein expression vector was transformed into engineering bacteria, and the recombinant protein expression strain was screened; after transforming the engineering bacteria, a single clone was picked and inoculated into the auto-induction complex medium, and cultured at 37 °C and 200 rpm for 18 h; the bacterial cells were collected by centrifugation; bacterial lysate was added to the bacterial cells, and then sonicated to obtain a precipitate; after washing the precipitate, a urea solution was added, and it was dissolved by shaking overnight and centrifuged, and the supernatant was collected; the supernatant was loaded onto the column, and the column was rinsed with the urea solution to wash away the impurity proteins, and the purified protein was eluted and collected.
[0033] d. The purified protein was placed in a dialysis bag and dialyzed by soaking in a gradient dialysis buffer solution.
[0034] Among them, the steps are specifically as follows: After transforming the recombinant plasmid into the commercialized Transetta(DE3) competent cells (TransGen Biotech), single colonies are picked and inoculated into 250 mL of auto-induction complex medium containing 0.1% kanamycin, and cultured at 37 °C and 200 rpm for 18 - 20 h. The cells are collected by centrifugation at 4,000 g for 10 minutes at 4 °C. 30 mL of bacterial lysis solution (containing 1% protease inhibitor mixture) is added to the cells, and then ultrasonic lysis (30% power, ultrasonic for 3 s, stop for 3 s) is carried out for 30 min. The precipitate is obtained by centrifugation at 10,000 g for 15 minutes at 4 °C. After washing the precipitate with PBS, 30 mL of high-concentration urea solution (20 mM Tris-HCl, 5 mM imidazole, 0.5 M sodium chloride, and 8 M urea) is added, and it is dissolved by shaking overnight at 4 °C. Centrifuge at 10,000 g for 20 min, and collect the supernatant. The supernatant is loaded onto the column at a flow rate of 10 column volumes per hour. The column is washed with 15 column volumes of high-concentration urea solution to wash away the miscellaneous proteins. Elution is carried out using high-concentration imidazole and urea solution, and the purified protein solution is collected. The purified protein is placed in a dialysis bag with a molecular weight cut-off of 50,000 and soaked in a gradient dialysis buffer solution, and each dialysis solution is dialyzed for 6 h. The composition of dialysis solution I is 25 mM Tris, 350 mM NaCl, 2 mM reduced glutathione, 196 μL oxidized glutathione, 250 mM imidazole, 4 M urea, 10% glycerol; the composition of dialysis solution II is 25 mM Tris, 200 mM NaCl, 2 mM reduced glutathione, 100 mM imidazole, 2 M urea, 10% glycerol; the composition of dialysis solution III is 25 mM Tris, 100 mM NaCl, 2 mM reduced glutathione, 0 mM imidazole, 100 mM urea, 10% glycerol; the composition of dialysis solution IV is 25 mM Tris, 50 mM NaCl, 2 mM reduced glutathione, 0 mM imidazole, 0 mM urea, 10% glycerol.
[0035] Example 2: A method for preparing a recombinant protein, comprising the following steps: a. According to the published and verified mouse FGF11b (MFGF11b) nucleotide sequence NM_001291104.2 in the NCBI database, the MFGF11b coding sequence is obtained by gene synthesis.
[0036] b. After purification, it is recombinated into the prokaryotic expression vector pET-30a(+)-GFP using homologous arms to obtain the pET-30a(+)-GFP-MFGF11b recombinant plasmid. The primers used in the homologous arm recombination operation include primers shown as MFGF11b-F2 or MFGF11b-R2.
[0037] c. Transform the recombinant protein expression vector into engineering bacteria, and screen to obtain recombinant protein expression strains; after transforming the engineering bacteria, pick monoclonal colonies and inoculate them into an auto-inducing complex medium, and culture at 37 °C and 200 rpm for 18 h; centrifuge to collect the bacterial cells; add bacterial lysis solution to the bacterial cells, then ultrasonically lyse to obtain a precipitate; after washing the precipitate, add urea solution, and dissolve it by shaking overnight and centrifuge, collect the supernatant; load the supernatant onto the column, wash the column with urea solution to wash away the impurity proteins, and elute and collect the purified protein.
[0038] d. Place the purified protein in a dialysis bag and soak it in a gradient dialysis buffer solution for dialysis. The remaining specific operation steps are the same as those in Example 1.
[0039] During the expression and purification of the protein in Example 1 and Example 2, 200 μL of the culture medium, bacterial cells, supernatant after bacterial cell disruption, precipitate after bacterial cell disruption, and purified protein were collected respectively, 50 μL of 5× loading buffer was added, boiled at 100 °C for 10 min, and after cooling, the protein was detected by SDS-PAGE electrophoresis. The test results are as Figure 1 shown. After protein purification, the bands of impurity proteins were significantly reduced.
[0040] The present invention discloses an application of a recombinant protein in promoting angiogenesis after spinal cord injury.
[0041] For the identification of the pro-angiogenic function of the recombinant protein: Thaw and resuscitate HUVEC cells and culture them. Plate the cells with good growth status. After 24 h of plating, mix 2 μg of zebrafish Fgf11a-GFP and mouse FGF11b-GFP recombinant proteins with the prepared liposomes respectively to prepare recombinant protein-liposome complexes, add them to the cell culture medium, and culture at 37 °C and 5% CO 2 conditions for 24 h. Add commercial Matrigel (Corning) to a 48-well plate and place it at 37 °C for 30 min. After it solidifies, digest and collect the HUVEC cells transiently expressing zebrafish Fgf11a-GFP and mouse FGF11b-GFP recombinant proteins, and inoculate them into the Matrigel at a cell density of 50,000 cells per well, and culture at 37 °C and 5% CO 2 conditions for 8 h, then place it under an optical microscope to observe the angiogenesis and take pictures. Statistical analysis was performed using ImageJ software. After transfection of HUVEC cells with Fgf11a-GFP and mouse FGF11b-GFP recombinant proteins, the number of formed blood vessels increased significantly. The specific experimental results are as Figure 2 shown.
[0042] The effect of the recombinant protein on angiogenesis after spinal cord injury: Eight-week-old female C57BL / B6 mice were raised. A GFP control group, a zebrafish ZFgf11a recombinant protein injection group, and a mouse MFGF11b recombinant protein injection group were set up, with 18 mice in each group. The injection dose of the recombinant protein was 20 μg / mouse. Before the injection of the recombinant protein, the mice were anesthetized by intraperitoneal injection of 1% sodium pentobarbital. The 8th - 10th thoracic laminae were opened, and the spinal cord at the 10th thoracic vertebra was struck with a striker to form a contusive spinal cord injury model. According to the injection dose, the recombinant protein was mixed with liposome in equal volume before injection, and then GFP, zebrafish ZFgf11a recombinant protein, and mouse MFGF11b recombinant protein were respectively injected in situ into the injury center using a microinjector at an injection speed of 1 μL. After injection, the injury area was sutured, and the mice were helped to urinate smoothly by squeezing and massaging every day. Four days after injection, the mice were anesthetized and then the spinal cords of the mice were dissected, and the protein content in the spinal cord was observed using green fluorescence in a live imaging instrument. In the present invention, the method of GFP (green fluorescent protein) is the same as the method of expressing the recombinant protein, and the vector used is the vector of the recombinant protein.
[0043] The spinal cord and the protein extraction reagent were mixed, homogenized, and total tissue proteins were extracted. The protein concentration was measured using a BCA kit. According to the protein concentration, an appropriate amount of 5×loading buffer solution and 1×PBS buffer solution were added to prepare WB protein samples. They were boiled at 100 °C for 10 min, and then the expression of the angiogenesis factor VEGFA at the spinal cord injury site was detected by western blot.
[0044] At the same time, the spinal cord was placed in 4% PFA solution and fixed at 4 °C for 24 h, and then dehydrated with 20% sucrose solution at 4 °C for 24 h; dehydrated with 30% sucrose solution at 4 °C for 24 h. After embedding with OCT embedding agent, the frozen tissue blocks were placed in a microtome to cut tissue sections with a thickness of 16 μm. The sections were blocked with 5% BSA at 37 °C for 30 min, the primary antibody was diluted with 1% BSA, and incubated overnight at 4 °C. They were rewarmed at 37 °C for 1 h. The primary antibody was diluted with 1% BSA at a ratio of 1:500 and incubated at 37 °C for 1 h. They were washed 3 times with 1×PBST buffer, 5 min each time. They were sealed with a mounting medium containing DAPI, and pictures were collected by laser confocal C2-2. The random areas of at least 3 images were statistically analyzed using Image J software, and the data results were processed by Graph Pad Prism 8.0.1 software to generate statistical graphs. Four days after protein injection, green fluorescence could still be observed at the spinal cord injury site, indicating that the recombinant protein still existed at the injury site. The specific results are as Figure 3 shown.
[0045] Four days after the injection of mouse and zebrafish FGF11 recombinant protein, the protein level of vascular endothelial growth factor VEGFA at the spinal cord injury site increased (see Figure 4), the immunofluorescence detection results of the neovascularization marker protein CD31 showed that the neovascular density was significantly increased (see Figure 5 ).
[0046] The specific embodiments described in the present invention are only illustrative of the spirit of the present invention. Those skilled in the art to which the present invention pertains can make various modifications or supplements to the described specific embodiments or use similar ways to substitute, but will not deviate from the spirit of the present invention or exceed the scope defined by the appended claims.
[0047] Although the present invention has been described in detail and some specific embodiments have been cited, it is obvious that various changes or modifications can be made by those skilled in the art without departing from the spirit and scope of the present invention.
Claims
1. A coding sequence of a recombinant protein, characterized in that: include: The coding sequence shown as SEQ ID NO.01 or SEQ ID NO.
03.
2. A recombinant protein, characterized in that: The recombinant protein is prepared using the coding sequence as claimed in claim 1, and the amino acid sequence of the recombinant protein is shown in SEQ ID NO.02 or SEQ ID NO.
04.
3. A method for preparing a recombinant protein, characterized in that: The following steps are involved: a. The zebrafish Fgf11a nucleotide sequence or the mouse FGF11b nucleotide sequence is amplified by PCR or gene synthesis to obtain the coding sequence shown in SEQ ID NO.01 or SEQ ID NO.03; b. Use homologous arms to recombine into prokaryotic expression vectors to obtain corresponding recombinant plasmid vectors.
4. The method for preparing a recombinant protein according to claim 3, characterized in that: The primers used in the PCR amplification operation include primers shown as SEQ ID NO.05 and SEQ ID NO.
06.
5. The method for preparing a recombinant protein according to claim 3, characterized in that: The primers used in the homology arm recombination operation include primers shown as SEQ ID NO.07, SEQ ID NO.8, SEQ ID NO.9 or SEQ ID NO.
10.
6. The method for preparing a recombinant protein according to claim 3, characterized in that: The method also includes step c, and the operation method of step c includes: after transforming the engineered bacteria, picking a single clone and inoculating it into an automatic induction composite culture medium for cultivation, and collecting the bacteria by centrifugation.
7. The method for preparing a recombinant protein according to claim 6, characterized in that: Add bacterial lysis solution to the bacteria, then ultrasonically lyse them to obtain a precipitate; after washing the precipitate, add urea solution, dissolve it under shaking overnight, centrifuge it, and collect the supernatant; load the supernatant onto the column, wash away impurities, elute and collect the purified protein.
8. The method for preparing a recombinant protein according to claim 7, characterized in that: The method also includes step d, and the operation method of step d includes: placing the purified protein in a dialysis bag and immersing it in a gradient dialysis buffer solution for dialysis.
9. A recombinant strain, characterized in that: Contains the coding sequence as claimed in claim 1.
10. Use of a recombinant protein in promoting angiogenesis after spinal cord injury, characterized in that: The recombinant protein is the recombinant protein according to claim 2.
Citation Information
Patent Citations
Medicinal composition for treating nerve injury diseases
CN112138143A
Desmocyte growth factor 11
CN1414101A
Use of human fibroblast growth factor 11 relative to angiogenesis
KR1020170014106A
Prolonged Anti-diabetic effect of fibroblast growth factor 1 (FGF1)
WO2016130683A1
Cited By
Coding sequence of recombinant protein, recombinant protein, recombinant protein-liposome nanoparticle, preparation method and application
CN120905233A
